Shots:
- The Chinese NMPA has approved Exdensur as an add-on maintenance therapy for asthma pts (≥12yrs.) characterised by an eosinophilic phenotype based on P-III (SWIFT-1: n=382) & (SWIFT-2: n=380) trials
- Exdensur reduced asthma exacerbations by 58% (SWIFT-1) & 48% (SWIFT-2) over 52wks., with results in Chinese pts (n=58, SWIFT-1) consistent with the overall population. Pooled data showed a 72% decrease in hospitalizations vs PBO + SoC & fewer hospital/ER events (1% & 4% vs 8% & 10%)
- Additionally, Exdensur is under NMPA review as an add-on therapy with intranasal corticosteroids for the treatment of adults with inadequately controlled CRSwNP
Ref: GSK | Image: GSK | Press Release
Related News: GSK Reports the EMA’s MAA Acceptance of Bepirovirsen to Treat Chronic Hepatitis B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
